Key Takeaways from the 2026 Biomarker Operations & Biospecimen Management Summit

The inaugural Biomarker Operations & Biospecimen Management Summit met in Boston on November 16–17, 2026. Billed by its organizers as a first-of-its-kind meeting, it brought together biomarker operations, translational, clinical laboratory, and biorepository professionals. Over two days the program followed the specimen from collection at the site, through consent and data integration, and into long-term storage. Here are the themes that stood out. 

1. Simplify and Standardize at the Site 

The Day One program opened under a blunt banner: garbage in, garbage out. Sessions focused on pre-analytical variability and standardizing collection, processing, and handling across global sites, so the samples reaching the lab are consistent enough to produce reliable biomarker data. 

A key theme was simplicity. Site staff often juggle a different lab manual for every sponsor and study, and that variation breeds confusion and collection errors. The push was toward simpler, standardized lab manuals in familiar formats, backed by site training and industry-wide norms, so sites collect and process samples correctly the first time. Closer collaboration between biomarker, laboratory, and clinical operations teams was presented as part of the same answer. 

The program also asked what role biomarker operations should play in protocol design. Involving operational partners earlier lets teams weigh site feasibility, collection requirements, and patient burden before a protocol is locked. 

The implication for everyone downstream: a biomarker result is only as good as the specimen behind it, and how that specimen is collected, stored and moved matters alongside how the assay performs.

2. From Chain of Custody to Chain of Usability 

One panel took up the idea of “chain of usability” as the next step beyond chain of custody. Custody records where a sample has been. Usability connects its integrity and provenance with the clinical, molecular, and consent context needed to decide whether it can actually be used. As the science becomes more precise, teams need to know whether the right sample exists, whether it fits the phenotype or genotype, and whether it is permitted for use before anyone retrieves or consumes it. 
Consent had its own block on the program. One session was titled “The Silent Killer of Biospecimen Value,” addressing poor consent content and management and the challenge of country- and site-level consent requirements. Another covered managing multiple consent types and tracking withdrawals in real time, so that a participant’s withdrawal is acted on across the entire sample lifecycle. A later session advised writing “future use” consent broadly but not vaguely: broad enough to allow testing for biomarkers identified later, specific enough to meet approval requirements, and written to cover assay development. Naming categories of testing, rather than listing individual assays, keeps options open without losing the detail regulators need. 

The practical point: a sample whose consent status is unknown is of limited use regardless of how well it has been stored. 

3. Building Standards and Connecting the Data 

Two program blocks dealt with fragmented data. One panel weighed building versus buying sample tracking technology – asking how to connect tracking systems with LIMS, CTMS and central lab databases without creating new silos – and whether translational science or clinical operations should own those decisions. Other sessions described digitizing the Schedule of Events, tracking samples in near real time from collection through testing, and using operational monitoring to catch emerging risks before they affect sample quality, timelines or inspection readiness. Linking sample results with clinical metadata was presented as the step that turns biomarker data into meaningful insight. 

Running through these sessions was a call to create shared standards. Sponsors, central labs and technology providers each deliver data in their own formats, which makes harmonization slow and cross-study comparison difficult. Common standards, a common language across sites, labs and vendors, and closer partnership between biomarker operations and data management on what is captured, in what format and who owns harmonization would let the industry stop solving the same problems study by study. 

Global trials add another layer. Sessions covered China’s HGRAC requirements, US rules on sharing biospecimens, and genetic data with countries of concern, EU IVDR and country-specific export restrictions – all of which shape where samples can be stored and how they can move. The recommended response was to build operating models with central lab partners that anticipate regulatory and geopolitical shifts, and to balance regulatory requirements against operational feasibility to avoid costly protocol amendments. 

4. AI: Human in the Lead, Not Just in the Loop 

The AI sessions started from the premise that biomarker operations remain highly manual and time-consuming, and looked at applying AI and automation to bottlenecks in the end-to-end sample flow. One approach described a structured initiative to identify targeted use cases, supported by user training, quality control, prompt standardization and attention to inspection readiness, with adoption tracked through defined success metrics, team surveys and operational dashboards. 

A question from the floor sharpened the discussion: rather than “human in the loop,” it should be “human in the lead.” As we read it, the distinction is between a person reviewing what an AI has already produced and people setting the direction and owning the decisions, with AI in a supporting role. That fits the program’s own framing of AI as a way to reduce manual work while preserving scientific and quality oversight. 

5. Long-Term Storage and Retrieval 

Two sessions in the closing storage block were especially practical. The first made the case that long-term storage keeps your options open, with retained samples available for future research, and offered three lessons: 

  • • Plan for future use at protocol design. Collect enough material across the schedule of assessments, design kits for multiple aliquots by splitting the same draw volume into more tubes and keep untouched backups for future research. 
  • • Choose a storage partner as you would a specialty lab. Think long-term and portfolio-wide, not study by study. Consider location, storage conditions for current and future studies (ambient, refrigerated, frozen, and LN2) and access to a digital inventory. Confirm a secure location, reliable temperature monitoring, accurate inventory, detailed sample information (including consent status), and the ability to ship out and take samples back. Engage that partner early: contracting, building the inventory and shipping a small first batch all take time, so don’t wait until the study is nearly over. 
  • • Track at the tube level. Box-level inventory hides what is inside and exposed to risk when personnel turn over. Tube-level detail, ideally ingested from electronic manifests and including temperature excursions, freeze/thaw history and consent, lets teams pick, ship and destroy exactly the right samples. Ask each lab whether it over-labels tubes, since that can complicate accession into long-term storage. 

The second framed retrieval as a handoff, not the finish line. Automation begins before a sample ever reaches the store: machine-readable identifiers, standardized tube and rack geometry, and connected metadata determine whether samples can move through automated workflows at all. Different collections need different strategies, so the store should fit the workflow rather than the other way round. At the point of retrieval, researchers need the correct specimen, with the correct context, in the correct format, delivered with identity and custody intact. The session urged teams to measure the distance from request to scientific readiness, including retrieval time, first-time-right picks, custody completeness and recollection avoided. 

Where GXP-Storage® Fits 

Altogether, the sessions point to one conclusion: a specimen’s value depends on the information that travels with it. Custody, condition, context, and retention obligations all must stay connected to the physical sample, from the day it arrives to the day it is used or disposed of. That is the problem GXP-Storage was built to solve. 

Our purpose-built facilities in the United States and United Kingdom store regulated materials across every temperature, from controlled ambient to cryogenic. Our validated GXP-Guardian® platform connects that physical inventory to the data that makes it usable: 

  • • One immutable chain of custody from receipt through final disposition, defensible in regulatory inspection. 
  • • Fragmented data brought together. GXP-Guardian imports CRO LIMS exports, patient consent, lab manifests, QC records, retention schedules and chain-of-custody documentation, harmonizes them into one validated schema, and controls exactly who can see what. 
  • • Real-time visibility across every site, status and geography in one federated view, helping eliminate duplication and waste. 
  • • Retention managed by regulatory event. Disposition is triggered when the obligation is met, never before and never years after. 
  • • Audit-ready documentation in seconds, with complete chain of custody, temperature records and QC history in one interface. 

Storage is not where a sample’s journey ends; it is where its future value is protected. GXP-Storage and GXP-Guardian give sponsors one harmonized, audit-ready research library, ready for the next scientific question. 

November 2026 

Contributed by: Christopher R Otto 

 

About GXP-Storage

GXP-Storage is the strategic partner in regulated material management for life sciences organizations navigating complex compliance requirements. Combining purpose-built facilities with the validated GXP-Guardian® digital platform, the company delivers total custody, real-time visibility and audit-proven compliance across every temperature—from controlled ambient to cryogenic. Trusted by global pharma, biotech, CDMO and healthcare organizations, GXP-Storage transforms storage from a compliance risk into a strategic advantage. Learn more at gxp-storage.com